|
May 21
|
PTC Therapeutics (PTCT) Up as EC Returns CHMP Opinion on DMD Drug
|
|
May 20
|
BeiGene's (BGNE) Shares Surge 32% in a Month: Here's Why
|
|
May 17
|
Eli Lilly's (LLY) Efsitora Matches Daily Insulins in A1C Control
|
|
May 17
|
Amgen's (AMGN) Tarlatamab Receives FDA Approval for SCLC
|
|
May 17
|
Ionis (IONS), Biogen Down on Ending Development of ALS Drug
|
|
May 15
|
FDA Delays Decision on Ascendis' (ASND) Hormone Therapy Filing
|
|
May 14
|
Allogene (ALLO) Q1 Earnings in Line With Estimates, Sales Lag
|
|
May 14
|
Novo Nordisk (NVO) Up 3% as Haemophilia Drug Meets Study Goals
|
|
May 14
|
Merck (MRK) Ends Keytruda Combo Melanoma Study Due to Futility
|
|
May 14
|
Bayer (BAYRY) Q1 Earnings Fall Y/Y on Lower Product Sales
|
|
May 13
|
Ligand (LGND) Moves to Strong Buy: Rationale Behind the Upgrade
|
|
May 13
|
Moderna (MRNA) Falls as FDA Extends Review Time for RSV Vaccine
|
|
May 13
|
Bristol Myers (BMY) Fails to Meet Goal in Opdivo NSCLC Study
|
|
May 10
|
Nektar's (NKTR) Q1 Earnings and Revenues Surpass Estimates
|
|
May 10
|
Insmed (INSM) Beats on Q1 Earnings, Posts Upbeat Pipeline Updates
|
|
May 10
|
Iovance (IOVA) Q1 Earnings Surpass, Sales Lag Estimates
|
|
May 10
|
Amicus (FOLD) Q1 Earnings Top, Sales Lag, '24 Outlook Updated
|
|
May 10
|
Ligand (LGND) Is a Great Choice for 'Trend' Investors, Here's Why
|
|
May 9
|
Catalyst (CPRX) Q1 Earnings Beat, Firdapse Sales Drive Revenues
|
|
May 9
|
CRISPR's (CRSP) Q1 Loss Narrower-Than-Expected, Sales Miss
|